...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Heart type fatty acid binding protein in relation to pharmacologic scintigraphy in coronary artery disease
【24h】

Heart type fatty acid binding protein in relation to pharmacologic scintigraphy in coronary artery disease

机译:心脏型脂肪酸结合蛋白与冠状动脉疾病中药物闪烁的相关性

获取原文
获取原文并翻译 | 示例

摘要

Background: Heart-type fatty acid-binding protein (H-FABP) is a marker of myocardial necrosis, but whether it increases during myocardial ischemia is not known. This study investigated whether serum levels of H-FABP change during adenosine stress testing and nuclear imaging in patients with stable coronary artery disease. Methods: Thirty stable patients with established coronary artery disease on their medications were studied. Sampling was performed before the stress test, at the end of adenosine infusion, as well as 1, 2 and 3 h after the completion of the infusion. Results: No difference in H-FABP serum levels were found at the five pre-specified time points in the overall group (p=0.99); furthermore, there was no significant difference regardless of the test result - positive (p=l) or negative (p=0.98). Conclusions: It is concluded that H-FABP does not change significantly during pharmacologic stress testing in patients with known coronary artery disease and there is no difference whether there is inducible ischemia or not.
机译:背景:心型脂肪酸结合蛋白(H-FABP)是心肌坏死的标志物,但在心肌缺血中是否增加是未知的。本研究研究了在稳定冠状动脉疾病患者的腺苷应激测试和核影像期间是否调查了H-FABP的血清水平。方法:研究了其药物冠状动脉疾病的30例稳定患者。在腺苷输注结束时进行对压力测试之前进行取样,在输注完成后的1,2和3小时。结果:在整个组中的五个预设时间点(P = 0.99)中发现了H-Fabp血清水平的差异;此外,无论试验结果如何,没有显着差异 - 阳性(p = l)或阴性(p = 0.98)。结论:结论是,在已知的冠状动脉疾病患者的药理应激测试中,H-FABP不会显着变化,无论是否存在诱导缺血,都没有差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号